Evidence-Based Reviews

Anticonvulsants for alcohol withdrawal: A review of the evidence

Current Psychiatry. 2021 February;20(2):19-29,33 | doi:10.12788/cp.0094

References

1. Trevisan LA, Boutros N, Petrakis IL, et al. Complications of alcohol withdrawal: pathophysiological insights. Alcohol Health Res World. 1998;22(1):61-66.
2. Borghesani P. Alcohol withdrawal. In: Nordstrom KD, Wilson MP, eds. Quick guide to psychiatric emergencies. Springer: 2018;209-215.
3. Grant BF, Goldstein RB, Saha TD, et al. Epidemiology of DSM-5 alcohol use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry. 2015;72(8):757-766.
4. Ungur LA, Neuner B, John S, et al. Prevention and therapy of alcohol withdrawal on intensive care units: systematic review of controlled trials. Alcohol Clin Exp Res. 2013;37(4):675-686.
5. Sachdeva A, Choudhary M, Chandra M. Alcohol withdrawal syndrome: benzodiazepines and beyond. J Clin Diagn Res. 2015;9(9):VE01-VE07.
6. Ashton H. Toxicity and adverse consequences of benzodiazepine use. Psychiatr Ann. 1995;25:158-165.
7. Bonnet U, Banger M, Leweke FM, et al. Treatment of acute alcohol withdrawal with gabapentin: results from a controlled two-center trial. J Clin Psychopharmacol. 2003;23(5):514-519.
8. Bonnet U, Specka M, Leweke FM, et al. Gabapentin’s acute effect on mood profile--a controlled study on patients with alcohol withdrawal. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):434-438.
9. Myrick H, Anton R, Voronin K, et al. A double-blind evaluation of gabapentin on alcohol effects and drinking in a clinical laboratory paradigm. Alcohol Clin Exp Res. 2007;31(2):221-227.
10. Malcolm R, Myrick L, Veatch L, et al. Self-reported sleep, sleepiness, and repeated alcohol withdrawals: a randomized, double blind, controlled comparison of lorazepam vs gabapentin. J Clin Sleep Med. 2007;3(1):24-32.
11. Myrick H, Malcolm R, Randall PK, et al. A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res. 2009;33(9):1582-1588.
12. Stock CJ, Carpenter L, Ying J, et al. Gabapentin versus chlordiazepoxide for outpatient alcohol detoxification treatment. Ann Pharmacother. 2013;47(7-8):961-969.
13. Schacht JP, Anton RF, Randall PK, et al. Effects of a GABA-ergic medication combination and initial alcohol withdrawal severity on cue-elicited brain activation among treatment-seeking alcoholics. Psychopharmacol. 2013;227(4):627-637.
14. Björkqvist SE, Isohanni M, Mäkelä R, et al. Ambulant treatment of alcohol withdrawal symptoms with carbamazepine: a formal multicenter double blind comparison with placebo. Acta Psychiatr Scand. 1976;53(5):333-342.
15. Ritola E, Malinen L. A double-blind comparison of carbamazepine and clomethiazole in the treatment of alcohol withdrawal syndrome. Acta Psychiatr Scand. 1981;64(3):254-259.
16. Agricola R, Mazzarino M, Urani R, et al. Treatment of acute alcohol withdrawal syndrome with carbamazepine: a double-blind comparison with tiapride. J Int Med Res. 1982;10(3):160-165.
17. Stuppaeck CH, Pycha R, Miller C, et al. Carbamazepine versus oxazepam in the treatment of alcohol withdrawal: a double-blind study. Alcohol Alcohol. 1992;27(2):153-158.
18. Malcolm R, Myrick H, Roberts J, et al. The effects of carbamazepine and lorazepam on single vs multiple previous withdrawals in an outpatient randomized trial. J Gen Intern Med. 2002;17(5):349-355.
19. Malcolm R, Myrick H, Roberts J, et al. The differential effects of medications on mood, sleep disturbance, and work ability in outpatient alcohol detoxification. Am J Addict. 2002;11(2):141-150.
20. Lambie D, Johnson R, Vijayasenan M, et al. Sodium valproate in the treatment of the alcohol withdrawal syndrome. Aust N Z J. 1980;14(3):213-215.
21. Hillbom M, Tokola R, Kuusela V, et al. Prevention of alcohol withdrawal seizures with carbamazepine and valproic acid. Alcohol. 1989;6(3):223-226.
22. Djokic´ G, Lazic´ D, Nenadovic´ M, et al. Lamotrigine augmentation in delirium tremens. Srp Arh Celok Lek. 2011;139(suppl 1):41-45.

Conclusion: The researchers concluded that physical symptoms disappeared quicker in the sodium valproate group than in the control group.²⁰

Hillbom et al²¹ evaluated the efficacy of sodium valproate vs carbamazepine vs placebo to prevent alcohol withdrawal seizures. A total of 138 participants were studied. Forty-three were assigned to the carbamazepine group, 46 to the sodium valproate group, and 49 to the placebo group. The RCT lasted 4 days. The initial medication doses were 1,200 mg/d. Participants in the carbamazepine group experienced more adverse effects than those in the sodium valproate or placebo groups (P < .001). As a result, approximately one-half of the participants in the carbamazepine group stopped taking the medication. This finding was dependent on the dose of carbamazepine; >800 mg/d resulted in poor tolerance to adverse effects. Seizures occurred among patients in all 3 arms of the study; in the sodium valproate group, 1 participant had a seizure vs 2 participants in the carbamazepine group and 3 in the placebo group. On the other hand, DT occurred only in the sodium valproate and placebo groups.

Conclusion: Researchers concluded that when using sodium valproate or carbamazepine to prevent alcohol withdrawal seizures in an outpatient setting, the adverse effects may outweigh the benefits.²¹

Lamotrigine

The characteristics of the lamotrigine study included in this review are summarized in Table 3.²²

Djokić et al²² evaluated the efficiency of lamotrigine in the treatment of DT. A total of 240 participants who met International Classification of Diseases-10 criteria for DT were randomized to a control group that was treated with anticonvulsants according to an NIAAA protocol (2004), or to an experimental group that was treated with lamotrigine. The CIWA-Ar and the Memorial Delirium Assessment Scale (MDAS) were administered for objective assessment of clinical symptoms, superimposed medical complications, general condition of the patient, adverse effects, and mortality rate. Statistically significant differences between the experimental and control groups were apparent after the third day of therapy, when a drop in the average CIWA-Ar score was observed in the experimental group, while the control group still had high scores (P < .01). After the fifth day of treatment, the differences in scores were more apparent, with the experimental group showing CIWA-Ar scores equal to those of persons with mild/moderate DT, while those in the control group still had high scores. After the tenth day, participants in the experimental group did not have any alcohol withdrawal symptoms, while control group participants were just beginning to get out of life-threatening danger. Death occurred in 4.1% of control group participants and 3.4% of experimental group participants; this difference in mortality rate was not statistically significant.

Continue to: Conclusion

Anticonvulsants for alcohol withdrawal: A review of the evidence

References

Lamotrigine

Pages

Recommended Reading